| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:30 - 08:40 | Opening Remarks | ||||||
| 08:40 - 09:00 | [Keynote Speech] | ||||||
| 09:00 - 09:30 | Session (1) From Immune Infiltration to Immune Intervention: The Changing Landscape of Breast Cancer Immunotherapy |
Sherene Loi
|
|||||
| 09:30 - 10:00 | Session (1) From Evidence to Consensus: The Evolution and Global Impact of the NCCN Breast Cancer Guidelines: A Perspective from the Founding Chair of the NCCN Guidelines Panel for Breast Cancer |
William John Gradishar
|
|||||
| 10:00 - 10:30 | Session (1) From Global to Local: Ethnic and geographic impact in the treatment of breast cancer patient |
Shigehira Saji
|
|||||
| 10:30 - 10:50 | Coffee Break | ||||||
| 10:50 - 11:30 | The sustainable efficacy of CDK4/6 inhibitor therapy in HR+/HER2- Node+ high-risk early breast cancer |
Marc Thill
|
|||||
| 11:30 - 12:00 | Session (1) Impact and pitfall of International guideline and real world practice |
William John Gradishar
Sherene Loi
Shigehira Saji
Marc Thill
|
Chiun-Sheng Huang
|
||||
| 12:00 - 12:45 | Luncheon Symposium (1) Treatment update for 1L HR+/HER2- mBC with PIK3CA mut. (Case sharing) |
Chi-Feng Chung
|
|||||
| 12:45 - 13:00 | Coffee Break | ||||||
| 13:00 - 13:40 | Session (2) Redefining the Therapeutic Role of TKIs in HER2-Positive Metastatic Breast Cancer |
Virginia Borges
|
|||||
| 13:40 - 14:20 | Session (2) Evolving Treatment Landscape in HER2-Positive Early Breast Cancer: The Integration of ADC Therapies |
Sibylle Loibl
|
|||||
| 14:20 - 15:00 | Session (2) Defining the Optimal Sequence in HER2+ MBC: Balancing Category 1 Evidence with Emerging Frontline Data |
Erica L. Mayer
|
|||||
| 15:00 - 15:20 | Coffee Break | ||||||
| 15:20 - 16:00 | Session (2) Longer survival and better quality of life: novel strategy of maintenance therapy in HER2 positive MBC |
Joohyuk Sohn
|
|||||
| 16:00 - 16:40 | Session (2) Improving Outcomes: Redefining High Risk and Care in HR+/HER2- Early Breast Cancer |
Dejan Juric
|
|||||
| 16:40 - 17:20 | Session (3) Translating ctDNA Dynamics into Clinical Strategy: Innovation of Next-Generation SERD in 1L HR+/HER2- mBC |
François-Clément Bidard
|
|||||
| 17:20 - 18:00 | Session (3) Addressing Unmet Needs in TNBC: The Evolving Role of ADC Therapies |
Ching-Hung Lin
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 09:30 - 09:50 | [TBCS-GBCC-JBCS-SSO] Joint Session: De-escalation of Breast Surgery: Who Can Safely Receive Less? |
Chin-Sheng Hung
|
|||||
| 09:50 - 10:10 | [TBCS-GBCC-JBCS-SSO] Joint Session: Can Axillary Surgery Be Safely Omitted After Neoadjuvant Therapy? |
Laura S. Dominici
|
|||||
| 10:10 - 10:30 | [TBCS-GBCC-JBCS-SSO] Joint Session: Breast Surgery in Young and High-Risk Patients: Where Is the Limit of De-escalation? |
Han-Byoel Lee
|
|||||
| 10:30 - 10:50 | [TBCS-GBCC-JBCS-SSO] Joint Session: Is There Still a Role for Surgery in De Novo Stage IV Breast Cancer? |
Sung Gwe Ahn
|
|||||
| 10:50 - 11:10 | [TBCS-GBCC-JBCS-SSO] Joint Session: Precision Breast Surgery in Asia: Lessons from Japan | ||||||
| 11:10 - 11:30 | [TBCS-GBCC-JBCS-SSO] Joint Session: Setting the Future Standard of Breast Surgery: The SSO Perspective |
Mediget Teshome
|
|||||
| 11:30 - 12:00 | [TBCS-GBCC-JBCS-SSO] Joint Session: Discussion |
Sung Gwe Ahn
Laura S. Dominici
Han-Byoel Lee
Mediget Teshome
Chin-Sheng Hung
|
|||||
| 14:00 - 14:05 | [Young Doctors Forum] Opening | ||||||
| 14:05 - 14:30 | [Young Doctors Forum] From Trials to Practice: Interpreting Global Evidence in Modern Breast Cancer Care |
Marc Thill
|
|||||
| 14:30 - 14:55 | [Young Doctors Forum] Building a Career That Matters: Leadership, Innovation, and Impact in Breast Surgery |
Michael Berry
|
|||||
| 14:55 - 15:00 | [Young Doctors Forum] Q&A |
Michael Berry
Marc Thill
|
|||||
| 15:00 - 15:05 | Break | ||||||
| 15:05 - 15:45 | [Young Doctors Debate] Can Axillary Surgery Be Completely Omitted in Biopsy-Proven cN1 Breast Cancer Patients Achieving Radiologic and Molecular Complete Response After Neoadjuvant Therapy? |
Chiao Lo
|
|||||
| 15:45 - 16:25 | [Young Doctors Debate] Should ctDNA-Guided Escalation and De-escalation Replace Conventional Adjuvant Therapy Decision-Making in Early Breast Cancer? |
Tom Wei-Wu Chen
|
|||||
| 16:25 - 16:30 | [Young Doctors Debate] Q&A Closing |
Jeong Eon Lee
|
|||||
| 16:30 - 16:50 | YDF/YDD Group Photo |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 10:30 - 16:00 | Oral Presentation | ||||||
| 16:30 - 18:00 | Nursing Care |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 11:10 - 11:50 | Let’s Meet the Master (1) Dejan Juric |
Dejan Juric
|
|||||
| 12:20 - 13:00 | Let’s Meet the Master (2) Antonio Toesca |
Antonio Toesca
|
|||||
| 13:30 - 14:10 | Let’s Meet the Master (3) François-Clément Bidard |
François-Clément Bidard
|
|||||
| 14:40 - 15:20 | Let’s Meet the Master (4) Sherene Loi |
Sherene Loi
|
|||||
| 16:10 - 16:50 | Let’s Meet the Master (5) William J Gradishar |
William John Gradishar
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:10 - 08:50 | Breakfast Symposium | ||||||
| 08:50 - 09:20 | Session (4) AI in BC Care: Translating AI into Precision Medicine |
Serene Goh
|
|||||
| 09:20 - 09:50 | Session (4) Surgical De-escalation After Neoadjuvant Therapy: When Less Is More |
Susan Boolbol
|
|||||
| 09:50 - 10:10 | Coffee Break | ||||||
| 10:10 - 10:40 | Session (4) Axillary Management in the Era of Sentinel Node Biopsy: Evolving Standards and Controversies |
Laura S. Dominici
|
|||||
| 10:40 - 11:10 | Session (4) Robotic Nipple-Sparing Mastectomy: Technique, Outcomes, and Future Directions |
Antonio Toesca
|
|||||
| 11:10 - 11:30 | Session (4) Discussion |
Susan Boolbol
Laura S. Dominici
Serene Goh
Antonio Toesca
|
|||||
| 11:30 - 12:10 | Session (5) Advancing the Management of ER+ HER2- mBC: Integrating Evidence and Experience |
Adam Matthew Brufsky
|
|||||
| 12:10 - 12:55 | Luncheon Symposium (2) Optimizing treatment in patients with HER2-positive early breast cancer by extended adjuvant therapy and the use of Neratinib in real-world practice |
Chin-Yao Lin
|
|||||
| 12:55 - 13:10 | Coffee Break | ||||||
| 13:10 - 13:50 | Session (6) HER3-DXd – Emerging ADC treatment strategies in metastatic HR+/HER2- breast cancer |
Min Hwan Kim
|
|||||
| 13:50 - 14:20 | Session (6) Redefining First-Line Treatment in HER2+ mBC: Insights from DESTINY-Breast09 |
Tom Wei-Wu Chen
|
|||||
| 14:20 - 14:35 | Coffee Break | ||||||
| 14:35 - 15:15 | Session (6) Solo or duet - elevating outcomes for patients starting 1L mTNBC therapy by anti-Trop2 ADC |
Dwan-Ying Chang
|
|||||
| 15:15 - 15:55 | Session (6) Practical Insights on Using TS-1 as Adjuvant Therapy in HR+/HER2– Early Breast Cancer: Cases, Tolerability, and Results |
Li-Kun Ko
|
|||||
| 15:55 - 16:15 | Session (6) Discussion TBD | ||||||
| 16:15 - 16:30 | Award Ceremony | ||||||
| 16:30 - 17:00 | Closing |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 09:30 - 10:10 | HR+ eBC的治療(lidERA/monarchE/NATALEE) |
Hsu-Huan Chou
|
|||||
| 10:10 - 10:50 | Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2–mBC | ||||||
| 10:50 - 11:30 | Real world experience of Eribulin for metastatic Breast Cancer | ||||||
| 11:30 - 12:10 | Effectiveness of CDK4/6 inhibitor treatment for HR+/HER2- metastatic breast cancer (TBD) |
Marc Thill
|
|||||
| 12:10 - 12:50 | Luncheon Symposium (3) | ||||||
| 12:50 - 13:10 | Breast Reconstruction After Breast Cancer Surgery: Lessons Learned from Aesthetic Fat Transplantation |
Tsai-Ming Lin
|
|||||
| 13:10 - 13:40 | The value of robotic breast surgery--- comments from outsiders versus insiders |
Antonio Toesca
|
Michael Berry
|
||||
| 13:40 - 14:10 | Training pathways and learning models of surgeons of robotic mastectomy |
Wen-Ling Kuo
|
Tristen Park
|
||||
| 14:10 - 14:40 | Logistic issues, teamwork and working models related to the robotic surgical practice |
Han-Byoel Lee
|
|||||
| 14:40 - 15:10 | The impact of Breast Reconstruction on robotic mastectomy outcomes |
Alice Yao
|
|||||
| 15:10 - 15:30 | Panel Discussion |